CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 24×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.91BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.07xvs all stocks
52-Week Change
28.24%vs all stocks
Market Capitalization
2.91BUSDvs all stocks (USD)
Enterprise Value
2.21BUSDvs all stocks (USD)
Forward P/E
-10.04xvs Biotechnology peers
Price to Book (MRQ)
4.22xvs Biotechnology peers
Enterprise to EBITDA
-8.36xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-22.67%vs Biotechnology peers
Return on Equity (TTM)
-35.83%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-264.40MUSDvs all stocks (USD)
Net Income (TTM)
-241.60MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-201.25MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-121.40MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-236.02MUSDvs all stocks (USD)
Pre-tax Income
-211.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
361.00KUSDFY2025 · Dec 31, 2025Net Income
-212.18MUSDFY2025 · Dec 31, 2025EBIT
-208.22MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-207.94MUSDFY2025 · Dec 31, 2025Research & Development
170.64MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.38MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.76MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.61MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-212.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-174.14MUSDFY2025 · Dec 31, 2025Free Cash Flow
-175.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
91.39MUSDFY2025 · Dec 31, 2025Interest Paid
2.79MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-212.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
281.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
34.34MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.16MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
186.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-933.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-849.59MUSDFY2025 · Dec 31, 2025Sale of Investments
456.22MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-394.30MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
450.11MUSDFY2025 · Dec 31, 2025Shares Outstanding
38.19MSharesUpdated Jul 19, 2026Float Shares
32.75MSharesUpdated Jul 19, 2026Shares Short
6.36MSharesUpdated Jul 19, 2026Short Ratio
9.01daysvs all stocks
Short % of Shares Outstanding
19.44%vs all stocks
% Held by Insiders
7.78%vs all stocks
% Held by Institutions
113.48%vs all stocks
Total Cash (MRQ)
730.16MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
19.11USDUpdated Jul 19, 2026Total Debt (MRQ)
31.06MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0451xvs Biotechnology peers
Current Ratio (MRQ)
24.00xvs Biotechnology peers
Book Value per Share (MRQ)
18.03USDUpdated Jul 19, 2026Total Assets
806.88MUSDvs all stocks (USD)
Total Current Assets
803.90MUSDFY2025 · Dec 31, 2025Total Liabilities
67.05MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.98MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
30.41MUSDFY2025 · Dec 31, 2025Total Current Liabilities
36.64MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
91.14MUSDFY2025 · Dec 31, 2025Other Short-term Investments
700.01MUSDFY2025 · Dec 31, 2025Accounts Payable
9.02MUSDFY2025 · Dec 31, 2025Short-term Debt
611.00KUSDFY2025 · Dec 31, 2025Long-term Debt
30.41MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-510.19MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
739.83MUSDvs all stocks (USD)
52-Week Low
40.00USDUpdated Jul 19, 202652-Week High
99.50USDUpdated Jul 19, 202652-Week Change
28.24%vs all stocks
Beta
2.07xvs all stocks
50-Day MA
71.00USDUpdated Jul 19, 2026200-Day MA
74.44USDUpdated Jul 19, 2026Avg 10-Day Volume
527.99KSharesUpdated Jul 19, 2026Avg 30-Day Volume
701.63KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-6.64USDUpdated Jul 19, 2026Other Income / Expense
45.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 24×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 24.00Industry median: 5.50Industry P95: 22.03Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.91B, above the global median of $1.15BNotable
Market cap (USD): 2,908,860,627Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharma Research Products Co., Ltd
Tier 1ProductionApproval-Gated PipelineRule
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Piramal Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Autobio Diagnostics Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule
Rubicon Research Limited
Tier 1ProductionApproval-Gated PipelineRule
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
PC Connection, Inc.
1 interpretationLow-Leverage Liquidity Configuration
Castle Biosciences, Inc.
1 interpretationLow-Leverage Liquidity Configuration
Dyne Therapeutics Inc.
1 interpretationLow-Leverage Liquidity Configuration